Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2227602 | 0.85 | USP2 (0.44) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL10416670 | 0.82 | LMNA (0.46) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL1524925 | 0.81 | USP2 (0.37) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL4861016 | 0.81 | LMNA (0.37) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL8413989 | 0.79 | USP2 (0.41) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL3056487 | 0.78 | LMNA (0.36) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL5802631 | 0.78 | LMNA (0.36) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL4726851 | 0.77 | USP2 (0.39) | USP2SLCO1B1LMNAL3MBTL1PDE4A | |
| SCHEMBL14639329 | 0.74 | LMNA (0.32) | USP2SLCO1B1LMNAPDE4A | |
| SCHEMBL14639283 | 0.74 | LMNA (0.32) | USP2SLCO1B1LMNAPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10443084-B2 | Naphthalene derived chromogenic enzyme substrates | GLYCOSYNTH LIMITED (GB) | 2019-10-15 | — | — | US | disclosed |
| US-20180355403-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | GLYCOSYNTH LIMITED (GB) | 2018-12-13 | — | — | US | disclosed |
| US-9938562-B2 | Naphthalene derived chromogenic enzyme substrates | GLYCOSYNTH LIMITED (GB) | 2018-04-10 | — | — | US | disclosed |
| EP-3066209-B1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | GLYCOSYNTH LTD (GB) | 2017-12-06 | — | — | EP | disclosed |
| US-20160298167-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | GLYCOSYNTH LIMITED (GB) | 2016-10-13 | — | — | US | disclosed |
| EP-3066209-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | Glycosynth Limited (GB) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015067927-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | GLYCOSYNTH LIMITED (GB) | 2015-05-14 | — | — | WO | disclosed |
| US-5155026-A | METHOD FOR DETERMINATION OF NAGASE AND REAGENT THEREFOR | SHIONOGI & CO., LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0180961-B1 | GLUCOSAMINE DERIVATIVES AND REAGENT FOR ASSAYING N-ACETYL-BETA-D-GLUCOSAMINIDASE USING THE SAME AS SUBSTRATE | MEIJI SEIKA KAISHA LTD. (JP) | 1991-05-29 | — | — | EP | disclosed |
| EP-0294804-A2 | Method for determination of NAGase and reagent therefor | SHIONOGI SEIYAKU KABUSHIKI KAISHA (JP) | 1988-12-14 | — | — | EP | disclosed |
| US-4754025-A | Glucosamine derivatives and reagent for assaying N-acetyl-β-D-glucosaminidase using the same as substrate | MEIJI SEIKA KAISHA, LTD. (JP) | 1988-06-28 | — | — | US | disclosed |
| EP-0180961-A2 | Glucosamine derivatives and reagent for assaying N-acetyl-beta-D-glucosaminidase using the same as substrate | MEIJI SEIKA KAISHA LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| US-4432973-A | ANTIULCER AGENTS, AND ANTICOAGULANTS | SOCIETE DE RECHERCHES INDUSTRIELLES (S.O.R.I.) (FR) | 1984-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10443084-B2 | Naphthalene derived chromogenic enzyme substrates | MGAM, UGDH, ME1 | USP2 1947/4885SLCO1B1 904/4885LMNA 2098/4885 |
| US-20160298167-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | CYP2R1, TDO2, XDH | USP2 1651/4885SLCO1B1 931/4885LMNA 1727/4885 |
| US-20180355403-A1 | NAPHTHALENE DERIVED CHROMOGENIC ENZYME SUBSTRATES | ME1, XDH, UGDH | USP2 1780/4885SLCO1B1 906/4885LMNA 2559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.